Capital Planning Advisors LLC reduced its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 7.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,717 shares of the biopharmaceutical company’s stock after selling 3,580 shares during the quarter. Bristol-Myers Squibb accounts for 1.1% of Capital Planning Advisors LLC’s holdings, making the stock its 28th biggest position. Capital Planning Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,492,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Tradewinds Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares in the last quarter. Blue Chip Partners Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 17 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 504 shares in the last quarter. American National Bank raised its holdings in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares in the last quarter. Finally, Heritage Trust Co bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $123,000. Institutional investors and hedge funds own 69.51% of the company’s stock.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.23% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/13/capital-planning-advisors-llc-reduces-position-in-bristol-myers-squibb-company-bmy.html.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $60.86 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The stock has a market cap of $99,609.57, a P/E ratio of 20.56, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. Bristol-Myers Squibb’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.77 earnings per share. equities research analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.
BMY has been the topic of a number of research reports. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 target price on the stock. in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $66.00 target price (up from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. UBS AG reissued a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Finally, Citigroup Inc. lifted their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $64.93.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.